State Street’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

State Street’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-583,000	Closed	-$56.9M	–	3831
2015 Q1	$56.9M	Buy	583,000 +52,350	+10%	+$5.54M	0.01%	1160
2014 Q4	$49.2M	Sell	530,650 -39,392	-7%	-$3.11M	﹤0.01%	1239
2014 Q3	$39.2M	Buy	570,042 +58,316	+11%	+$4.18M	﹤0.01%	1302
2014 Q2	$53.6M	Sell	511,726 -10,041	-2%	-$854K	0.01%	1201
2014 Q1	$43.3M	Sell	521,767 -14,275	-3%	-$1.32M	﹤0.01%	1285
2013 Q4	$34.7M	Buy	536,042 +59,679	+13%	+$3.54M	﹤0.01%	1402
2013 Q3	$30.2M	Buy	476,363 +32,768	+7%	+$1.61M	﹤0.01%	1447
2013 Q2	$18.6M	Buy	+443,595	New	+$20.2M	﹤0.01%	1671

State Street's GEVA Position: Q2 2015 in Review

State Street sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 583,000 shares — an estimated $56.9M sold.

State Street first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $56.9M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

State Street reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
State Street sold 583,000 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $56.9M.
State Street first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
State Street's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $56.9M in Q1 2015.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on State Street's 13F filing for Q2 2015, filed 13 Aug 2015.